Phase 1b/2 Study of Pivekimab Sunirine in Combination With Venetoclax/Azacitidine or Magrolimab for Patients With CD123-Positive Acute Myeloid Leukemia
IMMUNOGEN IS NOW PART OF ABBVIE
Together we will be working to make a remarkable impact for cancer patients and their communities of care, raising standards of care and advancing a dynamic oncology pipeline.